Perry William L, Weitzman Aaron
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Clin Adv Hematol Oncol. 2005 Mar;3(3):199-202, 237-8.
The ability to identify activated pathways that drive the growth and progression of cancer and to develop specific and potent inhibitors of key proteins in these pathways promises to dramatically change the treatment of cancer: A patient's cancer could be characterized at the molecular level and the information used to select the best treatment options. The development of successful therapies not only requires extensive target validation, but also new approaches to evaluating drug efficacy in animal models and in the clinic compared to the development of traditional cytotoxic agents. This article highlights Eli Lilly and Company's approach to developing targeted therapies, from target identification and validation through evaluation in the clinic. A selection of drugs in the Lilly Oncology pipeline is also discussed.
识别驱动癌症生长和进展的激活通路，并开发这些通路中关键蛋白的特异性强效抑制剂，有望极大地改变癌症治疗方式：可以在分子水平上对患者的癌症进行特征描述，并利用这些信息选择最佳治疗方案。成功疗法的开发不仅需要广泛的靶点验证，还需要与传统细胞毒性药物的开发相比，在动物模型和临床中评估药物疗效的新方法。本文重点介绍礼来公司开发靶向疗法的方法，从靶点识别与验证到临床评估。还讨论了礼来肿瘤学产品线中的一些药物。
